A carregar...
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
Ofatumumab is one of the three anti-CD20 monoclonal antibodies currently available for the treatment of chronic lymphocytic leukemia (CLL). The US Food and Drug Administration (FDA) approved the use of ofatumumab in patients with CLL refractory to fludarabine and alemtuzumab in 2009, and the Europea...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4725726/ https://ncbi.nlm.nih.gov/pubmed/26855591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S72845 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|